Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate Myriad’s ability to grow test volumes and expand its high‑margin oncology portfolio despite pricing pressure, positioning it for revenue acceleration from its 2026 product pipeline.

Key Takeaways

• Revenue flat, volume up 2% YoY
• MyRisk test volumes up 14% affected market
• Prolaris revenue grew 16% YoY
• GeneSight margin hit by payer policy
• MRD alpha launch begins next week

Pulse Analysis

Myriad Genetics continues to solidify its role in the rapidly expanding molecular diagnostics market, where demand for precise, actionable testing is outpacing traditional lab services. The Q4 results show that while headline revenue remained flat, the company delivered a 2% increase in test volume, driven by robust demand for hereditary cancer panels and prostate cancer assays. This volume growth underscores the effectiveness of Myriad’s EMR integrations and targeted commercial investments, even as average revenue per test fell 2% because of payer mix shifts, notably UnitedHealthcare’s GeneSight policy change. The modest margin compression highlights the sensitivity of diagnostic firms to reimbursement dynamics, a factor investors watch closely.

Looking ahead, Myriad’s pipeline could be a catalyst for top‑line acceleration. The PRECISE MRD alpha launch for breast cancer, slated for select oncology centers, aims to prove ultra‑sensitive minimal residual disease detection, a capability that could differentiate Myriad in the oncology continuum. Complementary initiatives include an AI‑enhanced Prolaris prostate test and the FirstGene multi‑prenatal screen, both slated for 2026. By reorganizing reporting into cancer care, prenatal health, and mental health pillars, Myriad signals a strategic focus that aligns resources with high‑growth segments and may improve transparency for stakeholders.

Financially, the company reaffirmed its 2026 guidance of $860‑$880 million revenue, with adjusted gross margin targets of 68‑69% and EBITDA of $37‑$49 million. A $225 million cash cushion and a $35 million commercial investment plan provide runway for the upcoming launches. However, risks remain, including potential delays in MRD regulatory approval and continued payer pressure on test pricing. Overall, Myriad’s blend of steady cash flow, expanding test portfolio, and disciplined capital allocation positions it for incremental growth, making it a noteworthy play in the precision‑medicine landscape.